Laser and light therapies for the treatment of necrobiosis lipoidica

被引:0
|
作者
Ali Rajabi-Estarabadi
Divya J. Aickara
Melanie Hirsch
Natalie M. Williams
Eric L. Maranda
Evangelos Van Badiavas
机构
[1] University of Miami Miller School of Medicine,Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery
来源
Lasers in Medical Science | 2021年 / 36卷
关键词
Necrobiosis lipoidica; Phototherapy; Psoralen ultraviolet a therapy; CO; laser; Pulsed dye laser; PDT; Photodynamic therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Necrobiosis lipoidica (NL) is a rare, inflammatory granulomatous skin disorder involving collagen degeneration. In recent years, several light and laser therapies have been proposed and used in the treatment of NL with variable outcomes. The aim of the study was to investigate the efficacy and safety of lasers and light therapies for the treatment of NL. A review of PubMed was conducted to search for studies using laser and light therapies for the treatment of NL. Articles that employed a combination of treatment modalities were excluded. Twenty-four studies were reviewed. Light and laser therapies used in these studies included CO2 laser, pulsed dye laser, methyl aminolevulinate (MAL)-photodynamic therapy (PDT), aminolevulinic acid (ALA)-PDT, ultraviolet A1 (UVA1) phototherapy, and psoralen plus ultraviolet-A (PUVA). PUVA was identified as the modality with the most available evidence (7 studies), followed by MAL-PDT and ALA-PDT (5 studies each), pulsed dye laser and UVA1 (3 studies each), and lastly CO2 laser (2 studies). Most modalities demonstrated variable efficacies and side effects with the exception of PDL, which consistently showed successful outcomes. Multiple dermatologic light and laser therapies have been investigated for the treatment of NL, including PUVA, ALA-PDT, MAL-PDT, pulsed dye laser, UVA1, and CO2 laser. However, a clear consensus on the preferred treatment is yet to be addressed. Each treatment option demonstrates both advantages and disadvantages that should be discussed with patients when selecting the treatment modality.
引用
收藏
页码:497 / 506
页数:9
相关论文
共 50 条
  • [21] NECROBIOSIS LIPOIDICA
    不详
    BRITISH MEDICAL JOURNAL, 1949, 1 (4616): : 1150 - 1150
  • [22] Necrobiosis lipoidica
    Chakrabarty, A
    Phillips, TJ
    WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 2003, 15 (02): : 59 - 61
  • [23] FIBRINOLYTIC AGENTS IN TREATMENT OF NECROBIOSIS LIPOIDICA
    RHODES, EL
    ANGIOLOGY, 1978, 29 (01) : 60 - 64
  • [24] Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica
    Hwang, Angelina
    Kechter, Jacob
    Li, Xing
    Bhullar, Puneet
    Boudreaux, Blake
    Severson, Kevin
    Hughes, Alysia
    Branch, Emily
    Sekulic, Aleksandar
    Pittelkow, Mark
    Mangold, Aaron
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB239 - AB239
  • [25] Tretinoin treatment of necrobiosis lipoidica diabeticorum
    Boyd, AS
    DIABETES CARE, 1999, 22 (10) : 1753 - 1754
  • [26] Cyclosporin A in the treatment of necrobiosis lipoidica diabeticorum
    DArgento, V
    Curatoli, G
    Filotico, R
    Foti, C
    Vena, GA
    JOURNAL OF DERMATOLOGICAL TREATMENT, 1997, 8 (02) : 123 - 125
  • [27] Intralesional etanercept for the treatment of necrobiosis lipoidica
    Zeichner, J
    Stern, D
    Lebwohl, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB57 - AB57
  • [28] NECROBIOSIS LIPOIDICA - TREATMENT WITH SYSTEMIC CORTICOSTEROIDS
    PETZELBAUER, P
    WOLFF, K
    TAPPEINER, G
    BRITISH JOURNAL OF DERMATOLOGY, 1992, 126 (06) : 542 - 545
  • [29] Necrobiosis Lipoidica
    Mitre, Victoria
    Wang, Connie
    Hunt, Raegan
    JOURNAL OF PEDIATRICS, 2016, 179 : 272 - U366
  • [30] NECROBIOSIS LIPOIDICA
    LATHROP, R
    BURGOON, CF
    ARCHIVES OF DERMATOLOGY, 1960, 82 (02) : 294 - 294